Drug intelligence / Profile preview

BR007

Development stage: Preclinical
Lead developer: Xiyuan Anjian Pharmaceutical
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

BR007 is a bone-targeting small molecule-drug conjugate (SMDC) developed by Brise Pharmaceuticals. It is designed to specifically inhibit the transforming growth factor-beta (TGF-β) receptor within bone tissue. The molecule consists of a TGF-β receptor inhibitor payload conjugated to a bisphosphonate-based targeting moiety, which facilitates localized delivery to the bone and minimizes systemic exposure. This targeted approach is intended to reduce the side effects typically associated with non-specific TGF-β inhibition. BR007 has been granted Orphan Drug Designation by the FDA for the treatment of bone-related conditions.

Other names: BR-007 Sodium saltBR007 Sodium saltBR 007 Sodium salt

Targets

TGFBR (TGF-beta receptor)

Beyond the preview

Go deeper on BR007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR007.

Explore the full profile